MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

Download PDF Copy

Editorial Checklist

Reviewed

MedaSorb Technologies CorporationOct 9 2009

NewsGuard 100/100 Score

MedaSorb Technologies Corporation (OTCBB: MSBT) and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant attached to the Series B financing completed in August 2008. Dr. Phillip Chan, Chief Executive Officer, stated, "We are pleased to have the continued support of our existing investors. These funds help provide additional runway to finance our ongoing European Sepsis Trial and the CE Mark application process."

Additional information regarding the warrant exercise can be viewed in the Company's 8-K filed with the SEC on October 9, 2009, which is available at http://www.sec.gov.

Source:

MedaSorb Technologies Corporation

Posted in:

Tags: Cancer, Chemotherapy, Cytokines, Dialysis, Exercise, Influenza, Pneumonia, Sepsis, Trauma

Comments (0)

Download PDF Copy

Suggested Reading

Researchers identify 4-gene signature to predict neonatal sepsis before symptoms

Researchers identify 4-gene signature to predict neonatal sepsis before symptoms

HNL Dimer as a promising biomarker for monitoring antibiotic treatment in sepsis

HNL Dimer as a promising biomarker for monitoring antibiotic treatment in sepsis

Personalized medicine approaches for sepsis based on immune response profiling

Personalized medicine approaches for sepsis based on immune response profiling

Study provides insights into trends and disparities of neonatal infectious diseases in LMICs

Study provides insights into trends and disparities of neonatal infectious diseases in LMICs

MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test

MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test

Half of sepsis patients face death within two years

Half of sepsis patients face death within two years

Changing antibiotic delivery method improves sepsis outcomes globally

Changing antibiotic delivery method improves sepsis outcomes globally

Cordyceps sinensis shows promise in treating sepsis-associated acute kidney injury

Cordyceps sinensis shows promise in treating sepsis-associated acute kidney injury

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Innovative AI tool targets missing data to enhance sepsis risk predictions